Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

Metformin and pioglitazone monotherapy have been proven to alter gut microbiota in diabetes and obesity. The present study aimed to investigated whether the combined administration of pioglitazone and metformin achieved superior protective effects on high-fat diet (HFD)-fed obese mice and elucidated...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongmei, Liu, Jieying, Zhong, Ling, Ding, Lu, Zhang, Qian, Yu, Miao, Li, Ming, Xiao, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592694/
https://www.ncbi.nlm.nih.gov/pubmed/36304148
http://dx.doi.org/10.3389/fphar.2022.1004617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592694/
https://www.ncbi.nlm.nih.gov/pubmed/36304148
http://dx.doi.org/10.3389/fphar.2022.1004617

Ejemplares similares